Roche’s Tecentriq Receives EC’s Approval as 1L Treatment for Metastatic Non-Small Cell Lung Cancer

 Roche’s Tecentriq Receives EC’s Approval as 1L Treatment for Metastatic Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-III IMpower110 study assessing the efficacy and safety of Tecentriq vs CT in 572 PD-L1-selected, CT-naïve participants in a ratio (1:1) with stage IV non-squamous or squamous NSCLC
  • Results: improvement in OS in people with high PD-L1 expression (20.2 vs 13.1mos.), safety was consistent with its known safety profile with no new safety signals identified, grade 3–4 treatment-related AEs (12.9% vs 44.1%)
  • An exploratory OS analysis in the PD-L1 high population showed a continued OS benefit @median follow-up of 31.mos. (20.2 vs 14.7). Tecentriq is the first single-agent cancer immunotherapy with 3 dosing options allowing administration every 2,3,& 4wks.

Click here to­ read full press release/ article | Ref: Roche | Image: Roche

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post